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Premature infants change from placental supply of mainly carbohydrates to an enteral 
supply of mainly lipids earlier in their development than term infants. The metabolic 
consequences hereof are not known but might have long-lasting health effects. In fact, 
knowledge of lipid metabolism in premature infants is very limited. We have quantified de 
novo lipogenesis and cholesterogenesis on the third day of life in seven premature infants 
(birth weight: 1319 ± 417 g; gestational age: 30 ± 2 wk). For comparison, five healthy adult 
subjects were also studied. All subjects received a 12 hours- [1-13C] acetate infusion, 
followed by mass isotopomer distribution analysis (MIDA) on lipoprotein-palmitate and 
plasma unesterified cholesterol. The fraction of lipoprotein-palmitate synthesized at the end 
of the infusion period was 5.4 ± 3.9 % in infants, which was in the same range as found in 
adult subjects on a normal diet suggesting that hepatic de novo lipogenesis is not a major 
contributor to fat accumulation in these premature neonates. The fractional contribution of 
newly synthesized cholesterol to plasma unesterified cholesterol was 7.4 ± 1.3 % after a 12 
h infusion. The calculated rate of endogenous cholesterol synthesis was 31 ± 7 mg/kg/day, 
a value ~ 3 times higher than that found in adult subjects (10 ± 6 mg/kg/day). These results 










The highest growth rate in a human life span occurs during the fetal period. During this 
rapid growth, the fetus requires significant amounts of cholesterol and fatty acids that may 
be acquired from maternal sources or synthesized de novo by the fetus itself. The relative 
contribution of either source is not known. Cholesterol is required for structural functions 
and as a precursor of various metabolically active compounds such as hormones, oxysterols 
and bile salts. Inborn errors in cholesterogenesis lead to severe congenital defects, such as 
the Smith-Lemli-Opitz syndrome (SLO), indicating that maternal supply cannot fully 
account for the demands during fetal development. Recently it was demonstrated that newly 
synthesized cholesterol activates Sonic hedgehog (Shh)1, a signalling protein essential for 
normal embryonic development, which delineates the importance of this metabolic 
pathway.  
Fatty acids are needed as structural components of membrane phospholipids, as a source 
of energy and, if metabolic regulation in the fetus is similar to that in the adult, as activators 
of specific transcription factors.2, 3 Most observations suggest that in early gestation these 
fatty acids are derived from maternal sources after crossing the placenta, followed by a 
gradual shift to de novo synthesis in fetal tissues with advancing gestation.4-7 Hepatic 
lipogenesis is quantitatively not important in adult human life in industrialised societies. 
However, it has been suggested to be of importance in the fetus.8 No experimental data 
exists to indicate that hepatic de novo lipogenesis is a major contributor to the fetal lipid 
accumulation normally observed in the third trimester of pregnancy. 
Because fat deposition and accretion of specific lipids occurs mainly during the last 
trimester of intrauterine development, the prematurely born neonate is prone to be deficient 
in specific metabolites (e.g., brain docosahexaenoic acid and carnitine) as well as in the 
enzymes needed for fat digestion and metabolism. Furthermore, one of the most important 
differences in fat metabolism between premature and term neonates is that the very low 
birth weight neonate is often maintained on total parenteral nutrition for substantial periods 
of time after birth. Most parenteral nutrition solutions do not contain cholesterol. Breast 
milk does contain significant quantities of cholesterol. However, it is evident that many 
human infants thrive on cholesterol-poor formulas. It is not clear whether or to what extent 
cholesterol neosynthesis compensates for variations in dietary cholesterol intake in 
premature infants. There are indications to suggest relationships between the developmental 
stage at birth, the type and duration of infant feeding and susceptibility to develop chronic 
diseases in adulthood, such as atherosclerosis and insulin-dependent diabetes mellitus.9,10 
The mechanism underlying these long-lasting effects of early nutrition are not known but 
may be related to the amount of cholesterol ingested and/or the fatty acid quality and 
quantity during specific, critical periods of development.  
The aim of this study was to gain insight in the contribution of hepatic de novo 
lipogenesis to overall lipid accumulation in premature infants. In addition, we set out to 
determine the rate of cholesterogenesis in premature infants without a substantial dietary 





plasma cholesterol and lipoprotein-palmitate with [1-13C]acetate, followed by mass 
isotopomer distribution analysis (MIDA). These results provide the background 
information that is essential for studies on the metabolic consequences of composition of 





Patients and study design 
Seven premature infants were studied (birth weight: 1319 ± 417 g; gestational age: 30 ± 2 
wk) (Table 1), starting two days after birth. All infants required mechanical ventilation and 
were admitted to the neonatal intensive care unit of the Beatrix Children’s Hospital in 
Groningen immediately after birth. The infants received parenteral feeding, which was 
initiated at 24 h after birth with a glucose intake of about 6 to 7 mg/kg/min during the time 
of the experiments. Parenteral feeding also included a lipid emulsion (Lipofundin 20 %) 
that was infused at a rate of 0.8 g/kg/day at the second day of life. A very limited enteral 
feeding schedule (7.0 ± 2.7 ml/day) was initiated on the day of the [1-13C] acetate infusion. 
The ingested amount of cholesterol via the enteral route was less than 3 mg/day and the 
amount of carbohydrates via the enteral route was less than 0.5 mg/kg/min during the time 
of the experiment. All mothers except one (patient 5) had received antenatal steroids. The 
experimental protocol did not interfere with standard treatment for this group of patients. 
Exclusion criteria were: congenital infection, metabolic disorders, maternal endocrine 
disorders (diabetes and thyroid disorders) and chromosomal abnormalities. Patients 
received a constant intravenous infusion of [1-13C] acetate (Isotec, Miamisburg, OH, 
U.S.A.) at a rate of 0.20 mmol/kg/h for 12 h. The start of the study (t=0) was defined by the 
start of [1-13C] acetate infusion. Blood samples of 0.5 ml arterial blood were taken before 
and 8, 10, 11, 12 h after start of the infusion (incorporation phase), and subsequently at 2, 4, 
6, 10, 21, 30 and 45 h after termination of the infusion (decay phase). The study protocol 
was approved by the Central Committee on Research Involving Human Subjects, the 
Netherlands, and written informed consent was obtained from the parents after the protocol 
had been fully explained.  
For comparison 5 healthy adult control subjects were studied (mean age 32 ± 15 years, 
64 ± 7 kg). All subjects were instructed to consume their regular diet until 22.00 h of the 
evening of the start of the study, at which time they started their fast till 09.00 h. At this 
time they received an oral liquid diet replacement (Nutridrink, Nutricia BV, The 
Netherlands) containing 39 percent of total energy as fat with no cholesterol, 13 percent as 
protein and 48 percent as carbohydrates, at an ingestion rate of 7 mg/kg/min of 
carbohydrates. At midnight, a [1-13C] acetate infusion (0.20 mmol/kg/h) was started for 12 
hours. Venous blood samples were taken before and 8, 10, 11, and 12 h after start of the 
infusion (incorporation phase), and subsequently at 1, 2, 4, 6, 18, 26, 42, 50, 66 and 74 h after 
termination of the infusion (decay phase). After cessation of the infusion, subjects were 
allowed their normal dietary intake. 




Table 1. Characteristics of premature infants. 
 
Patient Gender g (wk) b (g) p (%) a (h)   c (mmol/l) TG (mmol/l) 
1 M 30 1240 P10-25 50 1.82 0.51 
2 M 30 1435 P25-50 49 2.43 0.82 
3 M 30 1315 P10-25 49 2.01 0.73 
4 F 29 845 P5-10 43 0.89 1.00 
5 F 34 1785 P25-50 64 1.28 1.27 
6 F 30 1845 P50-90 42 1.32 0.81 
7 M 29 765 <P5 53 1.16 0.65 
Mean  30.4 1319  50 1.56 0.83 
SD  1.5 417  7 0.54 0.25 
 
Abbreviations used: g, gestational age; b, birth weight; p, percentile; a, age at start of study; 




Blood was collected from the patients and volunteers in EDTA tubes and was directly 
centrifuged to separate plasma and cells. The plasma was stored at –80 ˚C until further
processing. Cholesterol for gas chromatography/mass spectrometry (GC/MS) analysis was 
extracted from 100 µl of plasma with 2 ml of 95 % ethanol/acetone (1:1, v/v) according to 
Neese et al.11 Unesterified cholesterol was subsequently derivatized using N,O-bis-
(trimethyl)trifluoroacetamide with 1 % trimethylchlorosilane at room temperature. Samples 
were dried under nitrogen and dissolved in 500 µl of hexane. Triacylglycerol-rich 
lipoproteins were isolated from plasma by ultracentrifugation as described earlier.12 VLDL 
separated using this method does also include intermediate density lipoproteins (IDL) and 
potentially chylomicrons. Lipids were extracted from lipoprotein fractions with 2 ml 
methanol/hexane (4:1, v/v) and transmethylated to fatty acid-methyl esters using 
acetylchloride. Samples were dried under nitrogen and dissolved in 100µl hexane. 
Lipoprotein particle size was calculated according to Beil et al.13, using the formula D = 
(0.211*([TG]/[PL]) + 0.38) / 0.0213, in which D is the diameter in Å. Assay kits for 
determination of plasma and lipoprotein triglyceride and cholesterol concentrations were 
obtained from Hoffmann-La Roche Ltd (Basel, Switzerland) and for determination of 
lipoprotein phospholipid concentrations from Waco Chemical (Marburg, Germany). 
Enrichments of lipoprotein-palmitate and of cholesterol were measured by gas 
chromatography-mass spectrometry. Cholesterol TMS derivatives were separated with a 
HP 5890 Plus gas chromatograph (Hewlett-Packard, Palo Alto, CA, USA), using a 30 m x 
0.25 mm (0.2 µm film thickness) DB5 ms column (J&W Scientific, Falson, CA, USA) 
directly inserted into the ion source of a Quadrupole mass spectrometer, model SSQ 7000 
(Finnigan Matt, San Jose, CA, USA). The oven temperature was programmed from 150 to 





370 and 371 were monitored by selected ion recording using chemical ionization. For 
analysis of the methyl esters of lipoprotein-palmitate the same GC/MS mode as described 
above was used, equipped with a 20 m x 0.18 mm i.d. AT1701 column (0.4 µm film 
thickness, Alltech Associates Inc, Deerfield, USA). GC oven temperature increased from 
100 oC to 280 oC at 20 oC/min. They were analyzed at mass-to-charge ratio (m/z) 271, 272 
and 273 (mass isotopomers M0, M1 and M2) using chemical ionization and selected ion 
recording, with methane as moderating gas.  
 
Calculations 
The theoretical background of the MIDA technique is described in detail elsewhere.14, 15 
MIDA is a method for calculating the fraction of newly synthesized polymers and the 
isotope enrichments of their monomer precursor subunits in vivo during a stable isotope 
labeling experiment. By applying probability logic with mass spectrometric analysis of 
polymers, the enrichment of the precursor pool (acetyl-CoA) and the fractional biosynthetic 
rates of the polymer can be calculated. This technique allows us to determine the fraction of 
newly synthesized cholesterol and palmitate molecules in the plasma pool. After cessation 
of label incorporation, the rate constant of decay of cholesterol is determined by analyzing 
enrichments of the higher isotopomers to exclude the chance of continuing label 
incorporation. It then becomes possible to calculate absolute cholesterol synthesis rates, 
using an estimate of body unesterified cholesterol pool size. An estimation of 130 mg/kg 
body weight for the total body unesterified cholesterol pool was used, as proposed by Neese 
and Hellerstein11, to calculate absolute synthesis rates. The ‘rapidly miscible’ cholesterol 
pool supposedly includes liver, intestine and plasma. The following non-steady-state 
equation is used: K = k x f x pool size/(1-e-kt), where K (mg/kg/h) is the absolute rate of 
cholesterol synthesis, f (in %) is the fraction of newly synthesized cholesterol molecules 
and k (h-1) is the rate constant of isotopic cholesterol removal from plasma. Curves for the 
excess of isotopomer M+3 in premature infants and control subjects are shown in Figure 1. 
The 12 hour bloodsample was used for calculation of fractional synthesis rates of both 
cholesterol and lipoprotein-palmitate. Blood samples taken 1 to 72 hours after cessation of 
the infusion, the so-called decay phase, were used to calculate k. 
 
Statistical analysis 
All values are expressed as means ± SD. Significance of differences was calculated using 
the two-tailed Student’s t-test for normally distributed unpaired data or a Mann-Whitney U 





The clinical characteristics of the infants are shown in Table 1. All the infants had an 
appropriate size for their gestational age (AGA), except for patient 4 and 7 that were small  
 




Figure 1.  Excess of isotopomer M+3 after start of the infusion with [1-13C]acetate for   




for their gestational age (SGA). The mean age of the infants at start of the study was 50 ± 7 
hours. 
The fractions of circulating unesterified cholesterol (f) attributable to endogenous 
synthesis are shown in Table 2. After a 12-h infusion of 13C-labeled acetate, 7.4 ± 1.3 % of 
plasma unesterified cholesterol was derived from acetyl-CoA in the premature infants and 
3.2 ± 1.5 % in the adults. The fractional rate constant of decay (k) of endogenously labeled 
plasma cholesterol was 0.08 ± 0.02 h-1. This was not significantly different from the rate 
constant calculated for adults: 0.05 ± 0.04 h-1. Endogenous cholesterol synthesis was 39.9 ± 
10.8 mg/day or 31.2 ± 7.2 mg/kg/day in infants. Cholesterol synthesis rates were 9.8 ± 6.2 
mg/kg/day in adults. Thus, when normalized for body weight, cholesterol synthesis in 
premature infants was more than 3 times higher than in adults.  
The enrichments of the hepatic acetyl-CoA precursor pools (p) and the fractional 




























































Table 2. Cholesterol synthesis rates in premature infants. 
 
Patient p (%) f (%) K (h-1) K (mg/day) K (mg/kg/day) 
1 16.7 8.4 0.06 45.5 36.0 
2 16.7 8.8 0.07 50.9 39.0 
3 15.0 6.6 0.06 36.0 27.3 
4 10.7 8.6 0.12 34.7 41.0 
5 13.7 7.1 0.07 50.9 28.5 
6 13.3 5.6 0.07 40.8 22.1 
7 12.7 6.4 0.07 20.4 26.7 
Mean ± SD  14.1 ± 2.2 7.4 ± 1.3 0.08 ± 0.02 39.9 ± 10.8 31.2 ± 7.3 
Mean ± SD  10.3 ± 3.8 * 3.2 ± 1.5 * 0.05 ± 0.04  593 ± 287   9.8 ± 6.2 * 
 
Infusions of [1-13C] acetate and analysis of plasma unesterified cholesterol by GC-MS were 
performed as described in the text. Abbreviations used: p, isotopic enrichment of precursor 
pool; f, fraction of cholesterol derived from endogenous synthesis; k, rate constant for exit 
of labeled cholesterol from plasma; K, absolute synthesis rate of plasma cholesterol. Values 



















Stable isotope infusions and GC-MS analysis of palmitate-methyl ester from plasma 
lipoproteins were performed as described in the text. Abbreviations: p, enrichment of 
precursor acetyl-CoA subunits that entered newly synthesized lipoprotein-palmitate 
molecules; f, fraction of circulating lipoprotein-palmitate derived from endogenous 
synthesis. * Denotes significant difference (P < 0.05) from premature infants.
Lipoprotein Patient  
p (%) f (%/12 h) 
1 15.6 2.5 
2 10.8 2.8 
3 18.3 0.9 
4 11.9 11.6 
5 10.0 6.6 
6 11.6 9.3 
7 16.7 3.9 
Mean ± SD infants 13.6 ± 3.2 5.4 ± 3.9 
Mean ± SD adults   9.1 ± 3.3 * 2.3 ± 2.9 




The fraction of de novo lipogenesis was 5.4 ± 3.9 % in the premature infants and 2.3 ±  
2.9 % in the healthy adult subjects after a 12 h infusion. There were no differences between 
calculated cholesterol and lipoprotein-palmitate precursor acetyl-CoA enrichments in both 
subject groups (compare Tables 2 and 3). However, acetyl-CoA enrichments were 
significantly higher in infants than in adults that received [1-13C]acetate at similar infusion 
rates.  
The isolated lipoprotein fractions contained on average 58.0 ± 13.6 % triglycerides, 27.9 
± 10.6 % phospholipids and 13.7 ± 7.1 % total cholesterol (Table 4). The two premature 
SGA infants (patient 4 and 7) showed higher triglyceride contents of their lipoprotein 
particles than the AGA infants, and consequently, lower phospholipid and cholesterol 
contents. The calculated lipoprotein particle size of the two SGA infants was larger than 
those of the AGA infants (Table 4). 
 
 
Table 4. Composition and particle size of lipoproteins in premature infants. 
 
Patient TG PL TC particle size 
 % % % nm 
1 56.1 36.5 7.4 33.1 
2 51.7 35.3 13.0 32.4 
3 38.3 43.8 17.9 26.5 
4 77.5 18.5 4.1 59.4 
5 56.7 21.4 21.8 44.1 
6 51.8 23.5 21.8 39.7 
7 74.1 16.2 9.7 63.2 
Mean 58.0 27.9 13.7 42.6 
SD 13.6 10.6 7.1 14.0 
 
Patient 4 and 7 are small for their gestatio nal age (SGA). Abbreviations used:  





This study was designed to quantify the rates of cholesterogenesis and de novo lipogenesis 
in premature infants. The results of this study show that cholesterol synthesis in premature 
infants is relatively high, i.e., 3 times higher than in adults, during the first days of life. 
Hepatic de novo lipogenesis in lipoprotein-palmitate was relatively low in premature infants 
and similar to values reported in adults in this study and by others.15, 16  
The MIDA method has several advantages for the specific purposes of this study. First, 





products, i.e., cholesterol and fatty acids, which provides a highly accurate basis for 
calculation of actual synthesis rates. For instance, [U-13C]glucose has been used to calculate 
fractional synthetic rates of palmitate in humans17, which may underestimate the rate of de 
novo lipogenesis due to isotopic dilution in the precursor pool between plasma glucose and 
the precursor acetyl CoA pool. Another advantage of MIDA is that it allows the use of 
small blood samples (0.2 - 0.5 ml). Only for determination of the lipoprotein-palmitate 
enrichments, two samples of 1.0 ml blood were needed. For comparison, the deuterium 
incorporation method that also allows for quantification of fractional synthesis rate of 
cholesterol and palmitate requires blood samples of 8 ml.18-21 Di Buono et al.21 
demonstrated that the deuterium incorporation technique and MIDA for measurement of 
cholesterol synthesis in humans yielded comparable results for fractional and absolute 
cholesterol synthesis rates. It should be realized, that MIDA calculates the amount of 
cholesterol in liver, erythrocytes and plasma11 that is derived from endogenous synthesis 
over the course of the infusion period. The total body cholesterol synthesis is not measured, 
because tissue cholesterol synthesis that does not leave the cell or equilibrates with the 
plasma compartment will not be measured. This may lead to a certain degree of 
underestimation. The estimate of the unesterified cholesterol pool size, which is derived 
from a value calculated for adults11, may lead to underestimation of absolute 
cholesterogenesis in premature infants. For practical reasons, we selected a 130 mg/kg pool 
size for all subjects (infants and adults), although plasma cholesterol concentrations were 
slightly lower in the infants. On the other hand, larger liver and blood volumes per body 
weight are present in infants compared to adults.22 Liver cholesterol contributes twice as 
much to the rapidly miscible cholesterol pool size as plasma cholesterol does. If anything, 
we therefore expect the rapidly miscible cholesterol pool size in preterm infants to be 
larger. Choice of larger or smaller pool sizes would lead to proportionally higher or lower 
estimates of cholesterol synthesis, respectively.  
To our knowledge, four studies examining cholesterol synthesis in human infants as a 
function of dietary cholesterol intake have been reported.18-20,23 Using deuterium 
incorporation techniques, it has been estimated that fractional synthesis rate of cholesterol 
ranges from 2 to 11 %/day in infants, strongly depending on the type of feeding at 4 months 
of age. The differences in fractional synthesis rates have been attributed to the quantity of 
dietary cholesterol, which was 3-fold higher for breast-fed infants than for those fed regular 
formulas. As expected, the quantity of cholesterol intake was found to be negatively 
associated with the fractional synthesis rate. Several studies in animals and humans already 
indicated that the rates of sterol synthesis are much higher in the fetus than in the adult 
when presented on a per-gram tissue basis (reviewed24). The high rates of fetal sterol 
synthesis may be related to high expression levels or activities of transcription factors, such 
as sterol regulatory element binding proteins (SREBPs), although to the best of our 
knowledge no information has been published on their function during development .25  
Fat accumulates during the last trimester of intra-uterine life and accounts for about 16 % of 
the total weight at birth.26 Most fat is present in the form of white adipose tissue. Definite 
data on the contribution of de novo lipogenesis are not known. Studies indicate that the rate 




of hepatic fatty acid synthesis is substantial in the fetus.27-29 The fraction of de novo 
lipogenesis measured in this study in lipoprotein-palmitate in the premature infants varied 
between 0.9 and 11.9 %/12h. In adults on a normal Western diet the fractional contribution 
to VLDL-palmitate equaled less than 5 %, a value that may increase to nearly 30 % during 
high carbohydrate intake.30 Our results in adult subjects are in line with these data. The 
fractional lipoprotein-palmitate synthesis found in premature infants in this small study was 
not related to birth weight, gestational age or gender. The lack of a significant difference 
between the two groups might be related to the high variability. We performed a post hoc 
power calculation that showed that a sample size of 24 should be sufficient to test whether a 
significant difference (P < 0.05, power 90 %) is different between premature infants and 
adult controls. Hellerstein et al. suggested that lipogenesis in humans is a rudimentary 
metabolic process, possibly only of importance in the fetus31; our data show that newly 
synthesized palmitate by the liver makes up a large part of the lipids that are present in the 
blood compartment.  
Total parenteral nutrition (TPN) was initiated at 24 hours after birth and consisted of an 
amino acid mixture with glucose and a lipid emulsion. Hamilton et al.32 showed that 
intravenous lipid emulsions in premature infants result in a marked increase in cholesterol 
synthesis. Furthermore, it is well known that infusing lipids downregulates de novo 
lipogenesis. However, fatty acid synthesis and cholesterol synthesis rates were measured at 
a mean age of 50 ± 7 hours when exogenous lipid supply was still low (0.8 g/kg/day), 
making a large influence of TPN on these parameters unlikely. Furthermore, TPN did not 
equilibrate in the VLDL fraction after ultracentrifugation (data not shown). On the other 
hand, carbohydrates have a well-known stimulatory effect on de novo lipogenesis and 
subjects received mostly glucose during the course of the experiment. Even in this 
relatively stimulatory situation, hepatic de novo lipogenesis was low in both study groups, 
underscoring the conclusion that this pathway is not of major importance in premature 
infants. 
De novo synthesis of fatty acids depends on the substrate availability of precursors of 
acetyl-CoA and on the activity of the acetyl-CoA carboxylase and the fatty acid synthase 
complex. The enrichments of the acetyl-CoA pool found in the premature infants was 
higher than in the adult subjects that received the [1-13C]acetate infusion at the same rate, 
indicating a decreased acetyl-CoA pool size or an increased flux through the acetyl-CoA 
pool that supplied the precursors for cholesterogenesis and lipogenesis. It is therefore 
unlikely that a relative deficiency in lipogenic precursors was present in the premature 
infants. The identity of acetyl-CoA pools for cholesterogenesis and lipogenesis, however, 
cannot be relied upon. Separate cytosolic acetyl-CoA could, in theory, have a similar 
enrichment in distinct cholesterogenic and lipogenic precursor pools. Enriching the acetyl-
CoA pool might theoretically influence synthesis rates if they are precursor driven. 
However, in this study we found no correlation between acetyl-CoA pool enrichments and 






In this study we used adult subjects as a control group. Of course, this is not ideal, since 
cholesterol pool sizes and VLDL turnover rates might be different in adults and premature 
infants. Furthermore, dietary intake was not completely similar with a higher amount of 
lipids given to the adult subjects. However, since it was impossible to find parents of 
healthy newborn infants willing to let their baby be subjected to intravenous infusions and 
blood sampling, this experimental setup proved to be not feasible. Furthermore, comparing 
premature infants with adult subjects does provide information on whether hepatic de novo 
lipogenesis and cholesterogenesis are important in pre-term infants, since values in adults 
have been validated for their importance in lipid accumulation and cholesterol metabolism. 
All mothers, except one, received antenatal corticosteroid therapy to promote fetal 
maturation of especially the lungs. This treatment has been shown to reduce mortality, 
respiratory distress syndrome, and intraventricular haemorrhage in premature infants. 
Several animal and human studies have indicated that the effect of glucocorticoids on 
lipogenesis may be organ-specific, in favor of lipogenesis in the lung in comparison to that 
in the liver. 32, 33, 34 
 In summary, the present data show that cholesterogenesis is relatively high in premature 
infants. Furthermore, our data suggest that hepatic de novo lipogenesis is not a major 
contributor to fat accumulation in the premature infant shortly after birth. We speculate that 
extra-hepatic lipogenesis might be of more importance for the lipid accumulation in the 
fetus during the last trimester of pregnancy. It has been postulated, on the basis of animal 
and human studies35, 36, that long-lasting effects of early nutrition may lead to a disturbed 
lipid metabolism later in life and development of chronic diseases. These effects may be 
caused by persistent changes in lipid metabolism that are induced by early feeding. With 
MIDA it has become possible to study short-term effects of dietary cholesterol and fatty 
acid composition in formulas and in human milk on synthesis and turnover of lipids, thus 
providing a clue on how early nutrition may affect these parameters.  
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als het vergeten heuvelland 
tenzij het golvend in de hand 
binnen het gapen van de dood 
ontdekt en hopeloos ontbloot 
schreeuwt als vol vissen aan de kant 
van een gegiste sloot. 
